DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SURAKSHA DIAGNOSTIC LTD (SURAKSHA) share price today?

SURAKSHA DIAGNOSTIC LTD (SURAKSHA) is trading at ₹259 on the NSE, down 0.35% on the day. Source: DocStoX.

What is the PE ratio of SURAKSHA DIAGNOSTIC LTD?

SURAKSHA DIAGNOSTIC LTD has a price-to-earnings (PE) ratio of 41.9 in the Healthcare Services sector.

What is the market capitalisation of SURAKSHA DIAGNOSTIC LTD?

SURAKSHA DIAGNOSTIC LTD has a market capitalisation of approximately ₹1,346 crore.

SURAKSHA DIAGNOSTIC LTD

SURAKSHA·NSE·Healthcare Services

₹259.00▼ -0.90 (-0.35%)

Healthcare Services · Healthcare Service Provider

A steady, established business

Day₹257.00

₹261.40

52W₹224

₹33332%

Open

₹261.40

High

₹261.40

Low

₹257.00

Prev Close

₹259.90

Volume

13.3K

VWAP

₹258.65

Snapshot

Key fundamentals

Market Cap

₹1,346 Cr

P/E Ratio

41.91Expensive

P/B Ratio

5.73

EPS

₹6.18

Book Value

₹47.00

ROE

14.10%Average

ROCE

17.00%Decent

Dividend Yield

0.19%

Debt / Equity

0.53Moderate

Face Value

₹2.00

52W High

₹333.00

52W Low

₹224.10

Sector

Healthcare Services

Industry

Healthcare Service Provider

Avoid

None moatHigh uncertainty

Fair value estimate

₹55

▼ 78.7%downside

Trading at ₹259 — 79% above our estimate

BearFair valueBull

₹47₹55₹81

/100

Business quality — Solid

Growth 85Profitability 45Efficiency 23Valuation 47

Plain English

Our view

A steady, established business
Revenue compounding 18% over 3 years
Fundamental red flags (Piotroski 1/9)

Strengths

Revenue compounding 18% over 3 years
Profit growing 73% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

14% ROE fading to 13% over ~3 yrs, on ₹47 book

₹48

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹81

Analyst target

No analyst coverage

—

Blended fair value₹55

What the numbers say

Investment thesis

Bull case

Revenue compounding 18% over 3 years
Profit growing 73% a year

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

41.9Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

14.1%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.53Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,346 Cr

P/B

5.73

EPS

₹6.18

Div Yield

0.19%

What changed

Recent changes

Domestic institutions+0.6% stake last quarter
Promoters+0.10% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 41.9×

Growth

Strong

+18% rev CAGR

Profitability

Healthy

14.1% ROE

Financial health

Comfortable

D/E 0.53

Momentum

N/A

No technicals

Today

Trading activity

Delivery %59.7%

Turnover₹34.38L Cr

Trades852

VWAP₹258.65

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+17.7%

+17.2%

10Y

—

Profit

+72.9%

+38.9%

10Y

—

EPS

-59.7%

-41.9%

10Y

—

Profile

Pros

Company has delivered good profit growth of 31.7% CAGR over last 5 years

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 0.10 pts; domestic institutions added 0.57 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

49%

Promoter

Promoters

49.1%+0.10

Public

12.1%-0.52

FII / FPI

13.5%0.00

DII

23.1%+0.57

Others

2.2%

Total shareholders

67,107-3,856 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter49.10%

FII13.46%

DII23.14%

Public12.08%

Others2.22%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]